Arca biopharma announces third quarter 2023 financial results

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options westminster, colo., oct. 18, 2023 (globe newswire) -- arca biopharma, inc. (nasdaq: abio), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported third quarter 2023 financial results and provided a corporate update.
ABIO Ratings Summary
ABIO Quant Ranking